TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …

TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…

TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…

TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…

TS-065154 — Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.

TS-064843 — , T2022-244, T2020-109 : Cancer vaccines targeting a combination of B Cell epitopes to improve patient outcomes.

TS-064835 — The Need In healthcare, accurately assessing and managing pain is paramount for patient well-being and treatment efficacy. However, conventional methods of pain assessment rely heavily on verbal communication from patients, which poses challenges for individuals unable to express their pain verball…

TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…

TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-064244 — The Need: Organizations, particularly college campuses, are facing a growing challenge in addressing student mental health issues. The rising prevalence of severe psychological problems, anxiety disorders, and depression among students necessitates a proactive and effective solution. The existing ga…

TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…

TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…

TS-064133 — Classic galactosemia is a genetic condition that can lead to life-threatening complications, including feeding problems, failure to thrive, liver damage, bleeding, and sepsis. If a lactose-restricted diet is provided during the first ten days of life, the neonatal symptoms quickly resolve and reduce…

TS-064046 — Dermal substitute with engineered rete ridges improves epidermal-dermal communication and enhances burn wound treatment.

TS-063959 — The Need Millions of individuals suffer from constipation due to the inability to relax pelvic floor muscles during bowel movements, leading to discomfort and strained efforts. Current solutions, like the Squatty Potty, lack adjustability and portability, limiting their effectiveness for a diverse …

TS-063919 — An articulating end effector for additive manufacturing that utilizes robot-assisted endoscopic surgery to implant synthetic tissues at local defects through “keyhole” incisions in patients. This innovative technology T2019-145 is part of a portfolio that also includes T2017-363. To learn more about both technologies, please visit https://oied.osu.edu/find-technologies and search using the phrase: Endoscopic additive manufacturing of biomaterials.

TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.

TS-063433 — A new pharmacologic modality for treating AFib.

TS-063154 — Worldwide, 686,000 new head and neck (H&N) cancers are diagnosed yearly, and 375,000 people will die annually. Human papillomavirus (HPV) is responsible for an increasing subset of H&N malignancies called oropharyngeal squamous cell carcinomas (OPSCC). Although it has a better prognosis than…

TS-063091 — A gene therapy approach to address the specific needs of failing hearts.

TS-063069 — In the wake of the global pandemic caused by SARS-CoV-2, the need for rapid, accurate, and efficient diagnostic methods for respiratory viral infections has become more critical than ever. Traditional diagnostic methods, while reliable, are often time-consuming, labor-intensive, and lack the neces…

TS-062900 — This cutting-edge technology redefines the intubation process by guiding the endotracheal tube into the airway with exceptional precision.

TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types

TS-062764 — The Pulmonary Hypertension Outcomes Risk Assessment (PHORA): a PAH risk stratification tool.

TS-062762 — Pinpointing previously concealed sectoral differences in the diabetic retina to diagnose DR earlier.

TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.

TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications